A Blood Test for Colon Cancer Cleared the FDA. The Announcement Says It Flags 13.7 Percent of Advanced Precancerous Lesions.

Sourcing first, because it governs how every number below should be read. The figures in this piece come from a company announcement carried on a financial news wire, not from a publication by the Food and Drug Administration [1]. The approval is reported by Freenome, the test's developer, and the commercial terms are reported by Freenome and Abbott, its commercialization partner. This piece attributes the performance figures to that announcement rather than to the agency, because no FDA original was obtained.

What was announced: on July 27, Freenome said the FDA approved SimpleScreen CRC, a test that screens for colorectal cancer by reading cell-free DNA in a blood sample, for average-risk adults aged 45 and older [1]. Abbott will commercialize it exclusively in the United States beginning in fall 2026, positioned alongside its existing Cologuard test rather than replacing it, and the announcement says Abbott owes Freenome a $100 million milestone payment on approval [1].

The trial behind it, which the announcement calls PREEMPT CRC, enrolled more than 48,000 asymptomatic adults between 45 and 85 [1].

Now the two words that decide whether any screening test is worth having, in plain terms.

Sensitivity is how often a test comes back positive in people who actually have the condition. The announcement reports 81.1 percent sensitivity for colorectal cancer, which means that of 100 people in the trial who had colorectal cancer, roughly 81 got a positive result and roughly 19 did not [1]. Those 19 are the ones a screening program has to answer for.

Specificity is the mirror image. It is how often the test comes back negative in people who do not have the condition. The announcement reports 90.4 percent specificity for advanced colorectal neoplasia [1]. Invert that and roughly 9 or 10 of every 100 people without advanced neoplasia would get a positive result anyway and be sent for follow-up, which in colorectal screening means a colonoscopy. That inversion is our arithmetic on the announced figure. The announcement does not print it.

Then there is the number that does not travel in headlines. For advanced precancerous lesions, the announcement reports 13.7 percent sensitivity, rising to 30.7 percent for lesions with high-grade dysplasia [1].

Precancerous lesions are the target that makes cancer screening preventive rather than merely early-detecting. A lesion found and removed is a cancer that never happens. A test that flags roughly 14 of every 100 advanced precancerous lesions is not doing that job, and the announcement does not claim it is.

Both executives quoted say a version of this in their own way. Aaron Elliott, Freenome's chief executive, framed the approval as a scientific milestone: "Today's approval is an important validation of the scientific vision we've spent more than a decade building" [1]. Jake Orville, a senior vice president in Abbott's cancer diagnostics business, framed it as an addition rather than a replacement: "No single screening option will reach every patient. By adding SimpleScreen CRC alongside Cologuard, we are expanding choices available" [1].

Orville's framing is the strongest case for the test, and it holds up. A blood draw is a lower-burden procedure than a colonoscopy or a stool-collection kit, and a screening test that a patient will actually complete outperforms a better test the patient never takes. A test with 81.1 percent sensitivity for cancer, used by someone who was never going to get screened at all, is a real gain over nothing.

What the announcement does not contain is the part that decides who gets that gain. There is no price. There is no statement about insurance coverage, Medicare reimbursement or what a patient pays out of pocket [1]. A screening test's value is a function of who can actually obtain it, and the only dollar figure in this release is the $100 million milestone payment moving from Abbott to Freenome [1].

The other missing piece is independent assessment. Everything above is the developer's and the commercializer's characterization of their own product's trial results, distributed through a financial news wire [1]. No independent clinical evaluation of SimpleScreen CRC surfaced in this search.

The agency's own record is what would settle the rest. Until the FDA's publication of this approval is in hand, the accurate description of the news is narrower than the headline version: a company announced an approval and reported its own trial numbers, and those numbers contain one figure that is genuinely strong, one that is genuinely weak, and no answer at all on cost.